References
- Butt Y, Kurdowska A, Allen TC. Acute lung injury: a clinical and molecular review. Arch Pathol Lab Med. 2016;140(4):345–350.
- Mokra D, Kosutova P. Biomarkers in acute lung injury. Respir Physiol Neurobiol. 2015;209:52–58.
- Blondonnet R, Audard J, Belville C, et al. RAGE inhibition reduces acute lung injury in mice. Sci Rep. 2017;7(1):7208.
- Cherian SV, Kumar A, Akasapu K, et al. Salvage therapies for refractory hypoxemia in ARDS. Respir Med. 2018;141:150–158.
- Fan E, Brodie D, Slutsky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment. Jama. 2018;319(7):698–710.
- Estenssoro E, Dubin A. [Acute respiratory distress syndrome]. Medicina (B Aires). 2016;76(4):235–241.
- Lu Y, Song Z, Zhou X, et al. A 12-month clinical survey of incidence and outcome of acute respiratory distress syndrome in Shanghai intensive care units. Intensive Care Med. 2004;30(12):2197–2203.
- Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet. 2007;369(9572):1553–1564.
- Yu L, Da XW, Wu XL, et al. Simvastatin prevents lipopolysaccharide-induced septic shock in rats. J Huazhong Univ Sci Technolog Med Sci. 2017;37(2):226–230.
- He Y, Peng Y, Tao L, et al. Peroxiredoxin-1 aggravates lipopolysaccharide-induced septic shock via promoting inflammation. Biochem Biophys Res Commun. 2020;527(4):861–865.
- Wei JW, Huang K, Yang C, et al. Non-coding RNAs as regulators in epigenetics (Review). Oncol Rep. 2017;37(1):3–9.
- Youssef HMG, Marei ES, Rashed LA. Long non-coding RNA steroid receptor activator in polycystic ovary syndrome: possible association with metabolic syndrome. Clin Exp Obstet Gyn. 2019;46(5):757–762.
- Uchida S, Adams JC. Physiological roles of non-coding RNAs. Am J Physiol Cell Physiol. 2019;317(1):C1–c2.
- Patop IL, Wüst S, Kadener S. Past, present, and future of circRNAs. Embo J. 2019;38(16):e100836.
- Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675–691.
- Das A, Gorospe M, Panda AC. The coding potential of circRNAs. Aging (Albany NY). 2018;10(9):2228–2229.
- Wang Y, Liu J, Ma J, et al. Exosomal circRNAs: biogenesis, effect and application in human diseases. Mol Cancer. 2019;18(1):116.
- Qi X, Zhang DH, Wu N, et al. CeRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710–718.
- Zhong Y, Du Y, Yang X, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17(1):79.
- Zhang HD, Jiang LH, Sun DW, et al. CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2018;25(1):1–7.
- Altesha MA, Ni T, Khan A, et al. Circular RNA in cardiovascular disease. J Cell Physiol. 2019;234(5):5588–5600.
- Li JJ, Wang W, Wang XQ, et al. A novel strategy of identifying circRNA biomarkers in cardiovascular disease by meta-analysis. J Cell Physiol. 2019;234(12):21601–21612.
- Zhang F, Zhang R, Zhang X, et al. Comprehensive analysis of circRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of atherosclerosis in rabbits. Aging (Albany NY). 2018;10(9):2266–2283.
- Akhter R. Circular RNA and alzheimer’s disease. Adv Exp Med Biol. 2018;1087:239–243.
- Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–442.
- Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32(5):309–316.
- Shen S, Kong J, Qiu Y, et al. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis. J Cell Biochem. 2019;120(6):10069–10081.
- Klopfenstein D, Zhang L, Pedersen BS, et al. GOATOOLS: a python library for gene ontology analyses. Sci Rep. 2018;8(1):10872.
- Wang Z, Shang P, Li Q, et al. iTRAQ-based proteomic analysis reveals key proteins affecting muscle growth and lipid deposition in pigs. Sci Rep. 2017;7:46717.
- John B, Enright AJ, Aravin A, et al. Human microRNA targets. PLoS Biol. 2004;2(11):e363.
- Guo R, Zhang L, Meng J. Circular RNA ANKRD36 attends to lipopolysaccharide-aroused MRC-5 cell injury via regulating microRNA-31-3p. Biofactors. 2020;46(3):391–401.
- Riedlinger T, Bartkuhn M, Zimmermann T, et al. Chemotherapeutic drugs inhibiting topoisomerase 1 activity impede cytokine-induced and NF-κB p65-regulated gene expression. Cancers (Basel). 2019;11(6):883.
- Jin J, Xu W, Wan B, et al. Topotecan alleviates lipopolysaccharide-mediated acute lung injury via the NF-κB signaling pathway. J Surg Res. 2019;235:83–92.
- Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i1585.
- Dias-Freitas F, Metelo-Coimbra C, Roncon-Albuquerque R Jr. Molecular mechanisms underlying hyperoxia acute lung injury. Respir Med. 2016;119:23–28.
- Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in cancer. Cell. 2019;176(4):869–881.e13.
- Panda AC. Circular RNAs act as miRNA sponges. Adv Exp Med Biol. 2018;1087:67–79.
- Girstun A, Ishikawa T, Kowalska-Loth B, et al. Subnuclear localization of human topoisomerase I. J Cell Biochem. 2017;118(2):407–419.
- Li M, Liu Y. Topoisomerase I in human disease pathogenesis and treatments. Genomics Proteomics Bioinformatics. 2016;14(3):166–171.
- Nagaraja V, Godbole AA, Henderson SR, et al. DNA topoisomerase I and DNA gyrase as targets for TB therapy. Drug Discov Today. 2017;22(3):510–518.